Abiopharma

🔍 ARMEN GARO H (Executive)

Company: AGENUS INC (AGEN)

Report Date: 2026-04-03

Detailed Transactions and Holdings:

• Acquired 4,629 shares of Common Stock at $3.33 per share (Direct)
  Date: 2026-04-03 | Code: A | equity_swap_involved: false | shares_owned_after: 339,147.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 31,298.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 28,950.00 | Footnotes: F4

Footnotes:

• F1: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 3, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
• F2: $3.33 is the closing price of our Common Stock on April 2, 2026, the last trading day for the payroll date for the pay period ending April 3, 2026.
• F3: Shares are held in Dr. Armen's IRA accounts.
• F4: Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
• REMARKS: Chairman, Chief Executive Officer and Principal Financial Officer